icon-account icon-glass


Call us about Lamotrigine withdrawal help   


Have you tried getting off Lamotrigine only to suffer Lamotrigine Withdrawals? Even Tapering Lamotrigine can cause anxiety, aggression, mood disturbances, insomnia, and other Lamotrigine Withdrawal symptoms. This is why our nonprofit has taken a holistic approach to Lamotrigine Withdrawal for over 15 years, calming the nervous system and promoting sleep while you Taper Lamotrigine.  We are regularly asked how to Wean Off Lamotrigine, yet different Lamotrigine Taper rates are appropriate depending on your individual circumstances, including what other medications you are taking.  If you are seeking help to Get Off Lamotrigine, please let us help you control Lamotrigine Withdrawal and help you recover as you Taper Lamotrigine.* Please CONTACT our nonprofit for a Free Consultation today.


how it


Our Lamotrigine weaning program is a slow taper that allows you to step down from Lamotrigine under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Lamotrigine until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Lamotrigine withdrawal and support well-being.*

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Lamotrigine Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; goals; and interactions. Don't Wean Lamotrigine alone, work with our Prescription Drug Experts.*

Imagine being Free of Lamotrigine Dependency

- Proven Program completed In-Home with Expert Guidance

- Slowly Wean Lamotrigine

- All-Natural Nutraceuticals to help Ease Lamotrigine Withdrawal*

- Professional information on interactions

- Free Mentoring on our 24/7 private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)

 Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only



Is it Your Time to Start a New Journey?


Shanna - Lamotrigine Withdrawal

What an incredible program and resource you gave me through this whole withdrawal process.  Thank you!

Shanna - Lamotrigine Withdrawal Success Story

Rachel - getting off Lamotrigine

I am so grateful to Point of Return.  They always had words of encouragement and ensured me that I would be able to do this and I did.

Rachel - Lamotrigine Withdrawal Success Story

                                     using a Natural Approach

Lamotrigine withdrawal team

Our team has survived psychoactive drug withdrawal. More...

getting off Lamotrigine anywhere in the world

We've helped people in 78 countries and in every state of the USA. More...

Lamotrigine withdrawal - media coverage

We have extensive media coverage; television, print, radio. More...


Message sent, thanks! Will get back to your shortly.




    Lamotrigine (Lamictal) is marketed throughout the world as Lamotrigine, an anticonvulsant drug used for epilepsy and bipolar and off-label for depression, anxiety and other issues. Lamictal was the first drug (other than Lithium) approved for bi-polar. Approximately 10% of patients taking Lamotrigine suffer what is deemed a 'safe rash' that is actually an allergic reaction. Lamotrigine prescribing information has a black-box warning regarding life-threatening skin reactions that primarily occur in the first 2-8 weeks of therapy, or during withdrawal if Lamotrigine is stopped too quickly. 

    In December 1994 Lamictal / Lamotrigine was approved by the FDA as a treatment for partial seizures in adult patients; in 1998 it was approved for pediatric patients over 2 years of age; and in 2003 Lamictal was approved for Bipolar disorder.

    Approximately 10% of patients taking Lamictal suffer what is deemed a 'safe rash' that is actually an allergic reaction. Lamictal prescribing information has a black-box warning regarding life-threatening skin reactions that primarily occur in the first 2-8 weeks of therapy, or during withdrawal if Lamictal is stopped too quickly.

    Evidence has shown that women are more likely to have side effects from Lamicital than men. Female hormones decrease serum levels of Lamictal while there is a significant increase in the follicle stimulating hormone (FSH) and luteninizing hormone (LH) from Lamictal. FSH is secreted by the pineal gland and regulates estrogen and progesterone within the ovaries in women and the sperm count in men.

    Approximately 7% of patients experience a 'alerting effect' that causes intolerable insomnia. More severe side effects include aseptic meningitis and Stevens-Johnson syndrome. Meningitis is an inflammation of the protective membranes that cover the brain and spinal cord and Stevens Johnson syndrome is a serious condition where the skin of the patient literally burns from the inside out. Additionally, Lamictal binds to melanin-containing (pigment) tissues such as the iris of the eye. Long-term consequences of this are unknown at this time.

    In 2010 the FDA warned doctors and patients regarding Lamictal's serious side effects, yet the drug remains on the market today.

    Unless a life-threatening reaction to Lamictal is occurring, the drug should be tapered slowly due to the risk of seizure and debilitating withdrawal symptoms. Yet many find that even with a slow taper, Lamictal withdrawal symptoms interfere with every aspect of life.

    top of page



    shaking, confusion, dizziness, sweating, severe headache, insomnia, anxiety, burning or tingling sensations around the body, brain zaps / brain shivers, vertigo, light headedness, rushing noise in the head, agitation, negative, tearful, concentration problem, tremors, diarrhea, vomiting, reduced appetite, nightmares, excessive dreaming, gastrointestinal issues


    fever, rash, backache, blurred vision, chest pain, trouble sleeping, dizzy, double vision, drowsiness, dry mouth, nausea, head pain, infection, quivering, low energy, stomach cramps, uncoordination, anger, mental impairment, toxic effect on brain or spinal cord, anxiety, confusion, diarrhea, indigestion, joint pain, neck pain, mood changed, loss of appetite, pain, eyesight issues, weight loss 


    Severe: suicidal ideation, peptic ulcer, visual impairment, bronchospasm, hematemesis, Stevens-Johnson syndrome, exfoliative dermatitis, angioedema, toxic epidermal necrolysis, erythema multiforme, renal failure (unspecified), epididymitis, vasculitis, rhabdomyolysis, apnea, lupus-like symptoms, pancreatitis, disseminated intravascular coagulation (DIC), hepatic failure, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), myocarditis, aplastic anemia, red cell aplasia, pancytopenia, hemolytic anemia, agranulocytosis, aseptic meningitis, hemophagocytic lymphohistiocytosis 

    Moderate: blurred vision, ataxia, chest pain (unspecified), constipation, contact dermatitis, depression, migraine, nystagmus, amnesia, hyperreflexia, peripheral edema, edema, dyspnea, vaginitis, hot flashes, lymphadenopathy, atopic dermatitis, hallucinations, aphasia, memory impairment, dyskinesia, hypertonia, akathisia, hostility, psychosis, dysarthria, euphoria, hypertension, palpitations, sinus tachycardia, peripheral vasodilation, orthostatic hypotension, myasthenia, dysphagia, elevated hepatic enzymes, gastritis, photophobia, conjunctivitis, leukopenia, impotence (erectile dysfunction), hematuria, ejaculation dysfunction, urinary incontinence, neuritis, dystonic reaction, dysphoria, delirium, hyperalgesia, hyperesthesia, choreoathetosis, hypotonia, hepatitis, melena, colitis, stomatitis, glossitis, erythema, eosinophilia, anemia, lymphocytosis, thrombocytopenia, dysuria, urinary retention , cystitis, hyperbilirubinemia, hypothyroidism, hyperglycemia, goiter, mania, confusion, amblyopia, esophagitis, neutropenia, hyponatremia, splenomegaly 

    Mild: diplopia, vomiting, drowsiness, fever, dizziness, pharyngitis, nausea, rash, diarrhea, tremor, abdominal pain, asthenia, fatigue, back pain, cough, dyspepsia, dysmenorrhea, xerostomia, weight loss, diaphoresis, libido increase, agitation, irritability, emotional lability, hypoesthesia, hyporeflexia, arthralgia, myalgia, sinusitis, epistaxis, flatulence, weight gain, anorexia, increased urinary frequency, xerosis, vertigo, amenorrhea, libido decrease, hyperkinesis, malaise, paranoia, flushing, syncope, yawning, eructation, hypersalivation, gingivitis, appetite stimulation, tinnitus, urticaria, ecchymosis, menorrhagia, polyuria, acne vulgaris, alopecia, hirsutism, skin discoloration, hyperventilation, hiccups, parosmia, ptosis, maculopapular rash, leukocytosis, petechiae, nocturia, urinary urgency, headache, paresthesias, insomnia, anxiety, influenza, infection, rhinitis, pruritus, nasal congestion 


    Hemophagocytic lymphohistiocytosis, history of angioedema, serious rash

    Lamotrigine use is contraindicated in patients who have demonstrated hypersensitivity to lamotrigine (e.g., rash, history of angioedema, acute urticaria, extensive pruritus, mucosal ulceration) or other life-threatening hypersensitivity or serious immune-related events. Due to life-threatening serious rash (including Stevens-Johnson syndrome and toxic epidermal necrolysis), lamotrigine carries a boxed warning stating the drug should be discontinued if rash occurs at any time during treatment. It is important to note that discontinuation of lamotrigine may not prevent progression to a higher level of severity; therefore patients should be closely monitored. Age is the only factor currently known to predict the occurrence or severity of a rash, with pediatric patients at increased risk. Other possible but unproven factors include concurrent use of valproate, exceeding the initial recommended dose, or exceeding the recommended dose titration. Almost all cases of life-threatening rash have occurred within the first 2 to 8 weeks of treatment. However, a prolonged duration of therapy should not preclude the possibility of an association to the drug. Also, caution is advised when administering lamotrigine to patients with a history of rash or allergy to other anticonvulsants, since non-serious rashes have occurred 3 times more frequently in these patients during treatment with lamotrigine than in those without this history. Lamotrigine should not be resumed following prior discontinuation due to rash unless the benefits outweigh the risks. If the drug is reintroduced and it has been 5 half-lives or longer since the last dose, the manufacturer recommends reinitiating using initial dosing recommendations. Multiorgan hypersensitivity reactions, also known as drug reaction with eosinophilia and systemic symptoms (DRESS), have occurred. Some have been fatal or life threatening. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy in association with other organ system involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present. Early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present even though a rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Discontinue lamotrigine if an alternative etiology for the signs or symptoms cannot be established. Lamotrigine may also cause hemophagocytic lymphohistiocytosis (HLH), which is a rare but serious uncontrolled immune system response that may result in hospitalization and death. Severe inflammation occurs throughout the body leading to severe problems with blood cells and organs throughout the body. HLH typically presents with a fever (greater than 101 degrees F) and rash. Other signs and symptoms may include enlarged liver with pain, tenderness, or unusual swelling over the liver area in the upper right belly, swollen lymph nodes, yellow skin or eyes, unusual bleeding, or nervous system problems (seizures, trouble walking, difficulty seeing, or other visual disturbances). A diagnosis may be established if 5 of the following symptoms from the HLH-2004 diagnostic criteria are present: fever or rash, enlarged spleen (splenomegaly), cytopenias, elevated concentrations of triglycerides or low blood concentrations of fibrinogen, high concentrations of blood ferritin, hemophagocytosis identified through bone marrow, spleen, or lymph node biopsy, decreased or absent natural killer cell activity, and elevated blood concentrations of CD25 showing prolonged immune cell activation. Evaluate patients who present with fever or rash promptly, as early recognition is necessary to improve outcomes and reduce mortality. HLH may be confused with other serious immune-system reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

    top of page


    According to the FDA regarding Lamictal / Lamotrigine Withdrawal:

    Discontinuation Strategy in Bipolar Disorder: As with other AEDs, LAMICTAL / Lamotrigine should not be abruptly discontinued. In the controlled clinical trials, there was no increase in the incidence, type, or severity of adverse experiences following abrupt termination of LAMICTAL / Lamotrigine. In clinical trials in patients with bipolar disorder, 2 patients experienced seizures shortly after abrupt withdrawal of LAMICTAL / Lamotrigine. However, there were confounding factors that may have contributed to the occurrence of seizures in these bipolar patients. Discontinuation of LAMICTAL  / Lamotrigine should involve a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) unless safety concerns require a more rapid withdrawal.

    Withdrawal Seizures: As with other AEDs, LAMICTAL / Lamotrigine should not be abruptly discontinued. 

    In patients with epilepsy there is a possibility of increasing seizure frequency. In clinical trials in patients with Bipolar Disorder, 2 patients experienced seizures shortly after abrupt withdrawal of LAMICTAL. However, there were confounding factors that may have contributed to the occurrence of seizures in these bipolar patients. Unless safety concerns require a more rapid withdrawal, the dose of LAMICTAL should be tapered over a period of at least 2 weeks (see DOSAGE AND ADMINISTRATION). 





    top of page


    *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

    *The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

    * Testimonial results may vary person to person.

    *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.

    *This program is not meant to cure or prevent any disease or illness.

    *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..